SCHEMBL1027183

SCHEMBL1027183

CC(=O)Nc1cc(/C(C)=N/O)c(O)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 1/20 0.41
POLB P06746 5/20 0.41
RAB9A P51151 3/20 0.41
ESR1 P03372 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
ESR2 Q92731 2/20 0.38
KMT2A Q03164 2/20 0.37
LMNA P02545 2/20 0.37
PKM P14618 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
APOBEC3A P31941 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027184 1.00 NPC1 (0.41) NPC1MAPTHTTPOLBRAB9A
SCHEMBL1025443 0.94 NPC1 (0.41) NPC1MAPTHTTPOLBRAB9A
SCHEMBL1025442 0.94 NPC1 (0.41) NPC1MAPTHTTPOLBRAB9A
SCHEMBL1028607 0.83 NPC1 (0.46) NPC1MAPTHTTPOLBRAB9A
SCHEMBL774588 0.77 POLB (0.56) NPC1MAPTHTTPOLBRAB9A
SCHEMBL5888424 0.77 POLB (0.56) NPC1MAPTHTTPOLBRAB9A
SCHEMBL1027809 0.76 NPC1 (0.46) NPC1MAPTHTTPOLBRAB9A
SCHEMBL30007636 0.76 NPC1 (0.46) NPC1MAPTHTTPOLBRAB9A
SCHEMBL29819513 0.74 ALDH1A1 (0.58) NPC1MAPTHTTPOLBRAB9A
SCHEMBL7757072 0.73 ALDH1A1 (0.49) NPC1MAPTHTTPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 US disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 NPC1 450/4885MAPT 230/4885HTT 1284/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 NPC1 1230/4885MAPT 1767/4885HTT 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.